Spotlight

Our latest news.

January 3, 2024

On Target Laboratories Names Scott Huennekens as Executive Chairperson of the Board

Read More
November 16, 2023

On Target Laboratories Secures $30 Million for Commercialization of CYTALUX® (pafolacianine) injection

Read More
August 10, 2023

On Target Laboratories Granted New Technology Add-On Payment (NTAP) for CYTALUX® (pafolacianine) injection in Ovarian and Lung Cancer Indications

Read More
June 6, 2023

CMS Issues Two New ICD-10 PCS Codes for CYTALUX® (pafolacianine) injection

Read More
April 11, 2023

On Target Laboratories Names Ben Lundgren as Chief Executive Officer

Read More
March 27, 2023

On Target Laboratories Announces Publication in Journal of Thoracic and Cardiovascular Surgery Phase 3 ELUCIDATE Trial of CYTALUX® (pafolacianine) Injection for Intraoperative Imaging of Lung Cancer

Read More
December 16, 2022

On Target Laboratories Announces Expanded Indication of CYTALUX® (pafolacianine) injection for Detection of Lung Cancer During Surgery

Read More
September 12, 2022

On Target Laboratories Announces Publication in Journal of Clinical Oncology of Results from Phase 3 Trial of CYTALUX® (pafolacianine) Injection for Intraoperative Imaging of Ovarian Cancer

Read More
July 26, 2022

On Target Laboratories and Mauna Kea Technologies Further Explore Targeted Detection and Real-Time Diagnosis of Lung Cancer with a Molecular Imaging Agent

Read More
May 18, 2022

On Target Laboratories and Mauna Kea Technologies Demonstrate Intraprocedural Targeted Detection of Lung Cancer with a Molecular Imaging Agent

Read More
May 11, 2022

On Target Laboratories, Inc. Announces Presentation of the Results from the ELUCIDATE Phase 3 Trial for CYTALUX™ (pafolacianine) injection for Intraoperative Molecular Imaging of Lung Cancer

Read More
March 8, 2022

On Target Laboratories and Mauna Kea Technologies Announce a Novel Clinical Research and Product Development Collaboration

Read More
January 13, 2022

On Target Laboratories Completes ELUCIDATE Phase 3 Clinical Trial Investigating the Use of CYTALUX™ (pafolacianine) injection in Cancer in the Lung

Read More
November 29, 2021

On Target Laboratories Announces FDA Approval of CYTALUX™ (pafolacianine) injection for Identification of Ovarian Cancer During Surgery

Read More
May 20, 2021

On Target Laboratories, Inc. Announces Results of Phase 3 Trial for Pafolacianine for Intraoperative Illumination of Folate Receptor Positive Ovarian Cancer

Read More
March 24, 2021

On Target Laboratories Secures $21 Million for Development and Commercialization of Pafolacianine Sodium Injection

Read More
March 3, 2021

On Target Laboratories Announces U.S. FDA Acceptance and Priority Review of New Drug Application for pafolacianine sodium injection for Identification of Ovarian Cancer During Surgery

Read More
December 3, 2020

On Target Laboratories Announces the Appointment of Tommy Lee as Vice President, Clinical Operations

Read More
October 1, 2020

On Target Laboratories Announces the Appointment of Patrick Spangler as Chief Financial Officer

Read More
July 8, 2020

First Patient Enrolled in the Phase 3 ELUCIDATE Trial of Pafolacianine Sodium (formerly OTL38) in the Intraoperative Identification of Lung Cancer Lesions

Read More
January 27, 2020

Intraoperative Molecular Imaging of Non-Small Cell Lung Cancer Improves Outcomes for 26 Percent of Patients in Multi-Institutional Phase 2 Clinical Trial

Read More
October 15, 2019

Positive Phase 2 Study Results Published for On Target's Intraoperative Cancer Imaging Agent.

Read More
August 19, 2019

On Target Completes OTL38 Phase 2 Clinical Trial in Lung Cancer

Read More
August 12, 2019

On Target Laboratories Appoints Chief Executive Officer

Read More
October 15, 2018

On Target Laboratories Announces Publication Supporting Use of OTL78 to Highlight Prostate Cancer Lesions

Read More
November 3, 2017

On Target Laboratories Raises Additional Capital from H.I.G. BioHealth Partners, Elevate Ventures and Helsinn

Read More
Brand Strategy By Assembly
Developed By Alchemy + Aim